INDP is trading 8.4% down at $2.61 with no clear company-specific catalyst emerging so far.
- This pre-market weakness appears idiosyncratic, as there are no fresh news or filings tied directly to Indaptus Therapeutics.
- The move does not appear to be a reaction to broad macro headlines or sector-wide trends.
- Traders should monitor for potential new company updates, analyst actions, or regulatory developments later in the session.